1. Home
  2. VTAK vs AZTR Comparison

VTAK vs AZTR Comparison

Compare VTAK & AZTR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Catheter Precision Inc.

VTAK

Catheter Precision Inc.

HOLD

Current Price

$2.53

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Logo Azitra Inc

AZTR

Azitra Inc

HOLD

Current Price

$0.34

Market Cap

4.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VTAK
AZTR
Founded
2002
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.1M
4.2M
IPO Year
2018
2023

Fundamental Metrics

Financial Performance
Metric
VTAK
AZTR
Price
$2.53
$0.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
54.2K
314.3K
Earning Date
11-13-2025
11-12-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$730,000.00
N/A
Revenue This Year
$822.86
N/A
Revenue Next Year
$168.42
N/A
P/E Ratio
N/A
N/A
Revenue Growth
82.96
N/A
52 Week Low
$1.49
$0.30
52 Week High
$15.68
$4.33

Technical Indicators

Market Signals
Indicator
VTAK
AZTR
Relative Strength Index (RSI) 54.17 40.19
Support Level $2.26 $0.34
Resistance Level $3.06 $0.39
Average True Range (ATR) 0.25 0.03
MACD 0.08 0.01
Stochastic Oscillator 62.32 46.47

Price Performance

Historical Comparison
VTAK
AZTR

About VTAK Catheter Precision Inc.

Catheter Precision Inc is engaged in design, manufacture and sale of new and innovative medical technologies primarily focused in the field of cardiac electrophysiology, or EP. The Company's primary product is the View into Ventricular Onset System (VIVO or VIVO System), which is a non-invasive imaging system that offers 3D cardiac mapping to help with localizing the sites of origin of idiopathic ventricular arrhythmias in patients with structurally normal hearts prior to EP procedures. The VIVO system has achieved a CE Mark allowing it to be commercialized in the European Union and has been placed at several hospitals in Europe. Its newest product, the Surgical Vessel Closing Pressure Device (LockeT), is a suture retention device indicated for wound healing by distributing suture tension.

About AZTR Azitra Inc

Azitra Inc is an early-stage clinical biopharmaceutical company focused on developing therapies for precision dermatology using engineered proteins and live biotherapeutic products. Its discovery platform is screened for naturally occurring bacterial cells with beneficial effects. These microbes are then genomically sequenced and engineered to make cellular therapies, recombinant therapeutic proteins, peptides, and small molecules for the precision treatment of dermatology diseases. The company's product candidates include ATR-12, for treating the orphan disease and Netherton syndrome; ATR-04, a genetically modified strain of S. epidermidis for treating the papulopustular rash; and ATR-01, a potential treatment for ichthyosis vulgaris, a chronic, abnormally dry, scaly skin disease.

Share on Social Networks: